Before any new drug can be tried in people, regulators need evidence that it’s reasonably safe. Most of that evidence comes from preclinical safety studies, usually run by contract research organizations, or CROs. For an early-stage biotech, those studies take up a large part of the budget and much of the time before the first clinical trial, so mistakes in their design can be expensive.
Preventing them is Dominic Poulin’s specialty. He spent more than two decades at CROs, starting as an inhalation technician at CTBR in Montreal (now part of Charles River Laboratories). He rose to study director and later moved into client management, where he advised companies on study design. Since joining KreaMedica in 2022, he has worked on the client’s side of the table, helping companies plan their safety programs, oversee the lab work and review the results.
We spoke with him about building a safety program from the ground up, the pitfalls he helps companies avoid, and what happens when a study doesn’t go as planned.
KreaMedica describes itself as a general contractor for drug development. Where do you fit in?
I’d compare my role to the foreman on a construction site, the person in the white hard hat. I make sure the plans are ready and the right team is on board. Then I’m on site, ensuring the work is conducted according to the study plan, that the team is aligned on scientific objectives, and that any deviations or emerging findings are evaluated and addressed promptly to maintain the integrity and quality of the research.
In practice, I’m involved from the first discussions with a client. I work to understand what they need and design the studies around it. Once the studies are underway, I follow them closely and review the data and reports. I’m essentially an extension of the client’s team on the ground.
How would you describe toxicology to someone outside the industry?
Toxicology is how we find out what a drug could do to the body, and at what dose, before it reaches people. I always keep one question in the back of my mind: would I be comfortable if my own children had to take this drug? In the end, we do this work to protect the public.
Who do you usually work with?
Our clients vary a great deal. Some come to us very early, with a molecule and target disease but no formulation work yet. Others have finished their in vitro work and are ready to run the toxicology studies required for an IND, the application to begin testing in people. Some are further along, with 28-day studies completed and longer-term studies ahead. The products range from small molecules and antibodies to gene therapies and RNA-based treatments, across areas such as inflammation and oncology. That variety is why every program has to be designed case by case.
When a new client comes to you, often on a tight budget, where do you start?
The first question is how the drug works. A clear understanding of the mode of action shapes the whole design, including which animal species are relevant. The second is what kind of molecule it is. That, along with the disease it targets, largely determines which regulatory guidelines apply and which studies are needed.
Budget matters, of course. But one of the biggest hurdles we see is the lack of a clear plan for what studies are needed, how long it will take to reach the clinic, and how that will be funded. So, we start by giving clients a complete picture of everything they’ll need to reach Phase 1, including budget and timelines, and take it from there one step at a time.
Where do companies tend to run into trouble?
I wouldn’t always call them mistakes. More often, they’re assumptions, or an incomplete understanding of the requirements. I see two issues in particular.
The first is trying to answer too many questions in a single study. Adding endpoints can seem efficient, but too many can turn a study into chaos. Blood sampling collected too frequently, for example, increases stress on the animals and can affect the blood results you’re trying to measure. You end up with data that’s hard to interpret.
The second is cutting corners, either by skipping a step or by deciding a study isn’t needed because changes are not expected. Some programs allow flexibility, but any change must be scientifically sound and properly justified. When a step is skipped, the data is often not what it should be, and fixing that later can be costly. My role is to explain those risks clearly, before a decision is made.
Can you walk us through a time a study didn’t go as planned?
One particularly challenging program involved an inhaled therapy for a long-standing client. During development, the drug moved from a liquid formulation to a dry powder. Bridging studies confirmed that the two formulations behaved similarly in the body, so chronic toxicology studies began. Then came unexplained mortality among the animals, and the study had to be stopped early.
I worked closely with the CRO’s study team and carried out an extensive on-site review of the data. The initial investigation didn’t reveal any clear toxicological or operational cause. So we looked more closely at the aerosol itself and the particles the animals were inhaling. We came to suspect that the range of particle sizes was too small and increased the deposition of particles in the deep lungs, increasing the absorption and systemic exposure.
Because the drug’s target was in the upper respiratory tract, we redesigned the exposure system to generate larger particles that better matched the intended site of delivery. That resolved the issue, and the program was able to continue. It’s a good example of why formulation science, inhalation toxicology and aerosol engineering need to be considered together when you’re troubleshooting a complex problem.
What makes the relationship with a client work?
It comes down to trust. We need to understand where the client is heading, and they need to see the value that KreaMedica can bring. When that trust is in place, we become a big part of their team.
Some programs need expertise beyond the core team. How do you work with specialists brought in through KreaConnect?
It works much the same way. I’m involved in the early discussions with the consultant and client, and once the studies are running, I work closely with the consultant. A consultant might bring expertise in regulatory strategy or formulation, for example, and I bring the toxicology expertise and my experience running studies at CROs. The goal is for all of us to work as one team, with the client getting the benefit of the right expertise at the right time
Want to dive deeper? Dominic shares nine practical steps to build a toxicology program that bridges preclinical science and clinical goals to ultimately drive smarter development decisions. Read about it here: https://staging.kreamedica.com/designing-a-toxicology-program-around-your-first-clinical-trial/
Dominic Poulin is part of KreaMedica’s in-house team. When a program calls for additional expertise, he works alongside consultants brought in through KreaConnect, KreaMedica’s platform for matching biotech companies with experienced specialists in regulatory, CMC, pharmacology, toxicology and clinical development.